NEW YORK — Pfizer is submitting an application today for emergency use authorization for its COVID-19 vaccine.
The New York-based pharmaceutical giant says the vaccine, that it developed with its German partner BioNTech, is 95-percent effective in clinical trials.
Two shots have to be given three weeks apart and the vaccine must be stored at minus 94 degrees Fahrenheit.
The FDA is expected to take a few weeks to make a decision and an advisory committee review of the vaccine is tentatively scheduled for early December.
If the FDA grants approval, the vaccine would most likely be offered first to health care workers, the elderly, and people with underlying medical conditions.